C5236913_NCI_BRIDG_5_3 | Knowledge4COVID-19

Property	Value
?:definition	Specifies whether the agent\'s characteristic have been modified from those approved in the marketing authorization in a way that could affect its quality. EXAMPLE(S): OTHER NAME(S): NOTE(S): Modification may include a change in pharmaceutical form (e.g. over-encapsulation, colour, dilution, re-tabletting for blinding etc.) or removal from the primary packaging and repacking (e.g. removal from a blister and putting in a bottle).
?:hasCUIAnnotation	<https://research.tib.eu/covid-19/entity/C5236913>
?:hasGeneratedBy	<https://research.tib.eu/covid-19/SourceName/NCI_BRIDG_5_3>
?:type	<https://research.tib.eu/covid-19/vocab/AnnotationDefinition>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/C5236913_NCI_BRIDG_5_3>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/C5236913_NCI_BRIDG_5_3>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all